180922-57-0

Upstream product

• 180922-60-5 [2-((3aR,5S,6R,6aR)-6-Benzyloxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-1,1-difluoro-2-phenoxythiocarbonyloxy-ethyl]-phosphonic acid diethyl ester 
• 151076-11-8 3-O-Benzyl-5,6-dideoxy-6-(diethoxyphosphinyl)-6,6-difluoro-1,2-O-isopropylidene-β-D-ribo-hexofuranose 
• 5451-40-1 2,6 dichloropurine 
• 70798-12-8 1,2-O-isopropylidene-3-O-benzyl-α-D-ribofuranoside 
• 63593-02-2 3-O-benzyl-1,2-O-isopropylidene-α-D-ribo-pentodialdo-1,4-furanose 

Downstream Products

• 180922-61-6 {2-[(2R,3S,5R)-5-(6-Amino-2-chloro-purin-9-yl)-3-benzyloxy-tetrahydro-furan-2-yl]-1,1-difluoro-ethyl}-phosphonic acid diethyl ester 

Relevant academic research and scientific papers

Synthesis of 2-chloro-2'-5'-dideoxy-5'-difluoromethylphosphinyladenosine: A nonhydrolyzable isosteric, isopolar analog of 2-chlorodeoxyadenosine monophosphate

2-Chloro-2'-5'-dideoxy-5'-difluoromethylphosphinyladenosine (5) was synthesized in thirteen steps from 3-O-benzyl-1,2-O-isopropylidene-α-D-ribofuranoside (1), a carbohydrate which is substituted differently at the 2- and 3-positions, making possible selective deprotection and reductive deoxygenation at the 2'-position of a nucleoside subsequent to glycosylation. Purine nucleoside phosphonate 5 is an analog of the monophosphate ester of the potent, clinically effective immunomodulatory agent 2-chlorodeoxyadenosine (2-CdA), and was synthesized to present a potential means of circumventing drug resistance in target immune cells.